Podcast
Questions and Answers
For which of the following scenarios would whole exome sequencing be LEAST appropriate?
For which of the following scenarios would whole exome sequencing be LEAST appropriate?
- Identifying variants of a drug transporter gene with SNPs in an exon region.
- Identifying variants of a drug receptor gene with SNPs in the coding region.
- Identifying variants of a drug-metabolizing gene with SNPs in the coding region.
- Identifying variants of a drug transporter gene with SNPs in the noncoding region. (correct)
A gene test considers the following variants: *2, *3, *4, *8. An individual who has a *1/*9 diplotype is tested using the gene test. Which of the following would the individual's diplotype be reported as?
A gene test considers the following variants: *2, *3, *4, *8. An individual who has a *1/*9 diplotype is tested using the gene test. Which of the following would the individual's diplotype be reported as?
- *1/*1
- *2/*3
- *1/*4
- *1/*9 (correct)
Which of the following U.S. government agencies oversees clinical laboratories concerning accuracy and reliability of testing results?
Which of the following U.S. government agencies oversees clinical laboratories concerning accuracy and reliability of testing results?
- CMS (correct)
- DEA
- FDA
- CDC
Which technique is most commonly used as the basis for pharmacogenomics genotyping procedures?
Which technique is most commonly used as the basis for pharmacogenomics genotyping procedures?
An individual taking multiple medications metabolized by many different enzymes under genetic control is a candidate for pharmacogenomic testing. Which testing approach makes the most sense in this scenario?
An individual taking multiple medications metabolized by many different enzymes under genetic control is a candidate for pharmacogenomic testing. Which testing approach makes the most sense in this scenario?
When considering potential stigmatization related to genetic test results, which of the following groups would LEAST likely be of immediate concern regarding access to this information?
When considering potential stigmatization related to genetic test results, which of the following groups would LEAST likely be of immediate concern regarding access to this information?
Which of the following privacy and potential discrimination issues is NOT covered (prohibited) by GINA?
Which of the following privacy and potential discrimination issues is NOT covered (prohibited) by GINA?
Which of the following domains is LEAST likely to be encompassed by the legal aspect of ELSI (Ethical, Legal, and Social Implications)?
Which of the following domains is LEAST likely to be encompassed by the legal aspect of ELSI (Ethical, Legal, and Social Implications)?
Which of the following factors are most likely to influence the ready availability of genetic tests, impacting pharmacogenomic implementation?
Which of the following factors are most likely to influence the ready availability of genetic tests, impacting pharmacogenomic implementation?
What are the four components of the ACCE framework, funded by the CDC, used to guide the pharmacoeconomic evaluation of genetic testing?
What are the four components of the ACCE framework, funded by the CDC, used to guide the pharmacoeconomic evaluation of genetic testing?
Which of the following would NOT be considered a primary motivation from a patient's perspective when considering genetic testing?
Which of the following would NOT be considered a primary motivation from a patient's perspective when considering genetic testing?
Which viewpoint is a proponent of Direct to Consumer Genetic Testing most likely to favor?
Which viewpoint is a proponent of Direct to Consumer Genetic Testing most likely to favor?
Which public agency is responsible for overseeing the regulation of false and misleading advertising related to genetic testing?
Which public agency is responsible for overseeing the regulation of false and misleading advertising related to genetic testing?
For Genomic and Genetic Testing, which of the following does NOT typically fall under conditions for regulation?
For Genomic and Genetic Testing, which of the following does NOT typically fall under conditions for regulation?
Genetic Testing Reports for Germline variants as provided by Direct to consumer Testing Labs make use of what testing modality?
Genetic Testing Reports for Germline variants as provided by Direct to consumer Testing Labs make use of what testing modality?
What does a higher therapeutic index indicate regarding drug safety?
What does a higher therapeutic index indicate regarding drug safety?
If a drug is considered a prodrug, what must occur before it can exert its pharmacological effects?
If a drug is considered a prodrug, what must occur before it can exert its pharmacological effects?
If a patient is a poor metabolizer of CYP2C19, how might this affect the standard dose of clopidogrel?
If a patient is a poor metabolizer of CYP2C19, how might this affect the standard dose of clopidogrel?
A drug is primarily eliminated through hepatic metabolism. Which factor is MOST likely to significantly affect its elimination rate?
A drug is primarily eliminated through hepatic metabolism. Which factor is MOST likely to significantly affect its elimination rate?
Which of the following BEST describes a 'loss-of-function' genetic variant in a drug-metabolizing enzyme?
Which of the following BEST describes a 'loss-of-function' genetic variant in a drug-metabolizing enzyme?
The ready availability of genetic testing particularly for point of care (POC) testing is one barrier to pharmacogenomic implementation. Which of the factors listed below ARE likely to influence the ready availability of genetic tests?
The ready availability of genetic testing particularly for point of care (POC) testing is one barrier to pharmacogenomic implementation. Which of the factors listed below ARE likely to influence the ready availability of genetic tests?
Flashcards
Whole exome sequencing
Whole exome sequencing
Sequencing all the protein-coding regions in the genome, best for identifying variants in coding regions, not non-coding regions.
Comprehensive panel test
Comprehensive panel test
Multiple medications metabolized by different enzymes.
GINA exception
GINA exception
The Genetic Information Nondiscrimination Act prevents genetic information misuse. However, it does allow employers using genetic information as a part of a wellness profile.
ACCE Framework
ACCE Framework
Signup and view all the flashcards
Turnaround Time (TAT)
Turnaround Time (TAT)
Signup and view all the flashcards
Direct to Consumer Testing
Direct to Consumer Testing
Signup and view all the flashcards
Federal Trade Commission
Federal Trade Commission
Signup and view all the flashcards
Genetic Testing Reports
Genetic Testing Reports
Signup and view all the flashcards
Genomic and Genetic Testing
Genomic and Genetic Testing
Signup and view all the flashcards
Basis for pharmacogenomics analysis
Basis for pharmacogenomics analysis
Signup and view all the flashcards
Clinical Laboratories
Clinical Laboratories
Signup and view all the flashcards
Study Notes
- PHRM 6203 Review Questions were presented by Otito Iwuchukwu.
- The current run was last updated on April 10, 2025, at 3:11 pm.
- There were 15 activities, 82 participants, and an average of 29 responses leading to an average engagement of 37%.
Whole Exome Sequencing
- Whole exome sequencing is not appropriate for identifying variants of a drug transporter gene with SNPs in the noncoding region.
Gene Test Variants
- A gene test that considers the variants *2, *3, *4, *8 where an individual with a *1/*9 diplotype is likely to be reported as *1/*9.
US Government Agencies
- The Centers for Medicare and Medicaid Services (CMS) oversees clinical laboratories concerning the accuracy and reliability of testing results
Genotype Procedures
- Polymerase Chain Reaction is the basis for many of the genotype procedures available for pharmacogenomics analysis
Pharmacogenomic Testing
- A comprehensive panel test is most appropriate for an individual taking multiple medications metabolized by many different enzymes under genetic control who is to undergo pharmacogenomic testing.
Genetic Test Results
- When considering stigmatization, physicians would not be of immediate concern regarding genetic test results.
GINA Coverage
- GINA covers (prohibits) all privacy and potential discrimination issues EXCEPT employers using a person's genetic information as part of their wellness profile.
Legal Aspects of ELSI
- The legal aspect of ELSI encompasses sample ownership, genetic discrimination, and intellectual property.
Genetic Testing
- The ready availability of genetic testing, particularly for point of care (POC) testing, is one barrier to pharmacogenomic implementation with inadequate turnaround time (TAT) for results plus Equipment and Assay sensitivity and specificity influencing the ready availability of genetic tests.
ACCE Framework
- The 4 components of the ACCE framework funded by the CDC to guide pharmacoeconomic evaluation of genetic testing are: analytic validity, clinical validity, clinical utility, and ELSI.
Patient's Perspective for Conducting Genetic Testing
- Prenatal implantation genetic diagnosis is not considered a patient's perspective for conducting genetic testing.
Direct-to-Consumer Genetic Testing
- A proponent of Direct to Consumer Genetic Testing is likely to favor it increases health awareness and access to tests plus ensures patient privacy and freedom of choice.
Regulations of Advertising for Genetic Testing
- The Federal Trade Commission is the public agency overseeing the regulation of any false and misleading advertising for genetic testing.
Conditions for Regulation Except
- For Genomic and Genetic Testing, all of the following would fall under conditions for regulation EXCEPT Clinical Lab Preference.
Germline Variants Testing Modality
- Genetic Testing Reports for Germline variants as provided by Direct to consumer Testing Labs make use of Single gene sequence and Multi-gene panels testing modality.
Studying That Suits You
Use AI to generate personalized quizzes and flashcards to suit your learning preferences.
